Mind Medicine has developed a groundbreaking treatment named MM120 (lysergide d-tartrate) for generalised anxiety disorder (GAD).
MM120 is administered in a single dose within a closely monitored clinical environment, requiring no additional therapeutic interventions. Its effectiveness is notable, demonstrating rapid and sustained efficacy for up to 12 weeks following administration.
Belonging to the class of classic or serotonergic psychedelics, MM120 Lysergide is a synthetic ergotamine acting as a partial agonist at human serotonin-2A (5-hydroxytryptamine-2A [5-HT2A]) receptors.
The MMED008 trial was conducted as a multi-centre, parallel, randomised, double-blind, and placebo-controlled study. It enrolled 198 participants who were randomly assigned to receive a single dose of MM120 at varying concentrations (25, 50, 100, or 200 µg) or a placebo. These results indicate the promising potential of MM120 in treating anxiety, offering hope to those grappling with this condition daily.
The primary objective of the study was to establish the dose-response relationship of MM120 across four doses compared to a placebo, as measured by the change in the Hamilton Anxiety Rating Scale (HAM-A) from baseline to Week 4. Additionally, a key secondary objective was to evaluate this relationship from baseline to Week 8.
Generalised anxiety disorder (GAD) is a prevalent condition causing significant impairment and affecting millions of individuals.
The FDA has recognised the potential of MM120 by granting it breakthrough designation for the treatment of generalised anxiety disorder (GAD).
